Real-world evidence on the economic implications of CGRP-mAbs as preventive treatment of migraine
Abstract Background Calcitonin gene-related peptide (CGRP) monoclonal antibodies (mAbs) are approved in Europe as preventive treatment of migraine in patients with at least four monthly migraine days. Migraine gives rise to direct healthcare expenditures, but most of the economic burden of migraine...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2023-07-01
|
| Series: | BMC Neurology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12883-023-03302-7 |
| _version_ | 1827905467335049216 |
|---|---|
| author | Nikolaj Siersbæk Lærke Kilsdal Christian Jervelund Sonja Antic Lars Bendtsen |
| author_facet | Nikolaj Siersbæk Lærke Kilsdal Christian Jervelund Sonja Antic Lars Bendtsen |
| author_sort | Nikolaj Siersbæk |
| collection | DOAJ |
| description | Abstract Background Calcitonin gene-related peptide (CGRP) monoclonal antibodies (mAbs) are approved in Europe as preventive treatment of migraine in patients with at least four monthly migraine days. Migraine gives rise to direct healthcare expenditures, but most of the economic burden of migraine is socioeconomic. Evidence on the socioeconomic implications of CGRP-mAbs is, however, limited. There is an increasing interest in supplementing evidence from randomised controlled trials (RCTs) with real-world evidence (RWE) to aid clinical decision making and inform decision making for migraine management. The objective of this study was to generate RWE on the health economic and socioeconomic implications of administering CGRP-mAbs to patients with chronic migraine (CM) and episodic migraine (high-frequency episodic migraine (HFEM), and low-frequency episodic migraine (LFEM)). Methods Real-world data (RWD) on Danish patients with CM, HFEM, and LFEM were collected via two Danish patient organisations and two informal patient networks and used in a tailored economic model. Treatment effects of CGRP-mAbs on health economic and socioeconomic outcomes were estimated using a sub-sample of patients with CM who receive CGRP-mAb treatment. Results A total of 362 patients (CM: 199 [55.0%], HFEM: 80 [22.1%], LFEM: 83 [22.9%]) were included in the health economic model (mean age 44.1 ± 11.5, 97.5% female, 16.3% received treatment with CGRP-mAbs), and 303 patients were included in the socioeconomic model (15.2% received treatment with CGRP-mAbs). Health economic savings from initiating CGRP-mAb treatment totalled €1,179 per patient with CM per year on average (HFEM: €264, LFEM: €175). Socioeconomic gains from initiating CGRP-mAb treatment totalled an average gross domestic product (GDP) gain of €13,329 per patient with CM per year (HFEM: €10,449, LFEM: €9,947). Conclusion Our results indicate that CGRP-mAbs have the potential to reduce both health economic expenditures and the socioeconomic burden of migraine. Health economic savings are used as a basis for health technology assessments (HTAs) of the cost-effectiveness of new treatments, which implies that important socioeconomic gains may not be given enough importance in decision making for migraine management. |
| first_indexed | 2024-03-13T00:42:04Z |
| format | Article |
| id | doaj.art-e7a803784ad3423190d2dc5277b9c471 |
| institution | Directory Open Access Journal |
| issn | 1471-2377 |
| language | English |
| last_indexed | 2024-03-13T00:42:04Z |
| publishDate | 2023-07-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Neurology |
| spelling | doaj.art-e7a803784ad3423190d2dc5277b9c4712023-07-09T11:17:12ZengBMCBMC Neurology1471-23772023-07-0123111110.1186/s12883-023-03302-7Real-world evidence on the economic implications of CGRP-mAbs as preventive treatment of migraineNikolaj Siersbæk0Lærke Kilsdal1Christian Jervelund2Sonja Antic3Lars Bendtsen4Copenhagen EconomicsCopenhagen EconomicsCopenhagen EconomicsPain and Headache Clinic, Aarhus University HospitalDepartment of Neurology, Danish Headache Center, Copenhagen University Hospital - RigshospitaletAbstract Background Calcitonin gene-related peptide (CGRP) monoclonal antibodies (mAbs) are approved in Europe as preventive treatment of migraine in patients with at least four monthly migraine days. Migraine gives rise to direct healthcare expenditures, but most of the economic burden of migraine is socioeconomic. Evidence on the socioeconomic implications of CGRP-mAbs is, however, limited. There is an increasing interest in supplementing evidence from randomised controlled trials (RCTs) with real-world evidence (RWE) to aid clinical decision making and inform decision making for migraine management. The objective of this study was to generate RWE on the health economic and socioeconomic implications of administering CGRP-mAbs to patients with chronic migraine (CM) and episodic migraine (high-frequency episodic migraine (HFEM), and low-frequency episodic migraine (LFEM)). Methods Real-world data (RWD) on Danish patients with CM, HFEM, and LFEM were collected via two Danish patient organisations and two informal patient networks and used in a tailored economic model. Treatment effects of CGRP-mAbs on health economic and socioeconomic outcomes were estimated using a sub-sample of patients with CM who receive CGRP-mAb treatment. Results A total of 362 patients (CM: 199 [55.0%], HFEM: 80 [22.1%], LFEM: 83 [22.9%]) were included in the health economic model (mean age 44.1 ± 11.5, 97.5% female, 16.3% received treatment with CGRP-mAbs), and 303 patients were included in the socioeconomic model (15.2% received treatment with CGRP-mAbs). Health economic savings from initiating CGRP-mAb treatment totalled €1,179 per patient with CM per year on average (HFEM: €264, LFEM: €175). Socioeconomic gains from initiating CGRP-mAb treatment totalled an average gross domestic product (GDP) gain of €13,329 per patient with CM per year (HFEM: €10,449, LFEM: €9,947). Conclusion Our results indicate that CGRP-mAbs have the potential to reduce both health economic expenditures and the socioeconomic burden of migraine. Health economic savings are used as a basis for health technology assessments (HTAs) of the cost-effectiveness of new treatments, which implies that important socioeconomic gains may not be given enough importance in decision making for migraine management.https://doi.org/10.1186/s12883-023-03302-7CGRP-mAbsReal-world evidenceSocioeconomic gainsHealth economic savingsIndirect costDirect cost |
| spellingShingle | Nikolaj Siersbæk Lærke Kilsdal Christian Jervelund Sonja Antic Lars Bendtsen Real-world evidence on the economic implications of CGRP-mAbs as preventive treatment of migraine BMC Neurology CGRP-mAbs Real-world evidence Socioeconomic gains Health economic savings Indirect cost Direct cost |
| title | Real-world evidence on the economic implications of CGRP-mAbs as preventive treatment of migraine |
| title_full | Real-world evidence on the economic implications of CGRP-mAbs as preventive treatment of migraine |
| title_fullStr | Real-world evidence on the economic implications of CGRP-mAbs as preventive treatment of migraine |
| title_full_unstemmed | Real-world evidence on the economic implications of CGRP-mAbs as preventive treatment of migraine |
| title_short | Real-world evidence on the economic implications of CGRP-mAbs as preventive treatment of migraine |
| title_sort | real world evidence on the economic implications of cgrp mabs as preventive treatment of migraine |
| topic | CGRP-mAbs Real-world evidence Socioeconomic gains Health economic savings Indirect cost Direct cost |
| url | https://doi.org/10.1186/s12883-023-03302-7 |
| work_keys_str_mv | AT nikolajsiersbæk realworldevidenceontheeconomicimplicationsofcgrpmabsaspreventivetreatmentofmigraine AT lærkekilsdal realworldevidenceontheeconomicimplicationsofcgrpmabsaspreventivetreatmentofmigraine AT christianjervelund realworldevidenceontheeconomicimplicationsofcgrpmabsaspreventivetreatmentofmigraine AT sonjaantic realworldevidenceontheeconomicimplicationsofcgrpmabsaspreventivetreatmentofmigraine AT larsbendtsen realworldevidenceontheeconomicimplicationsofcgrpmabsaspreventivetreatmentofmigraine |